Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
Daily summary: Nervous anticipation, SaaS sell-off and weak macro data
“SaaS-pocalypse” continued
US OPEN: The market calms down ahead of earnings season
Amazon pours $25B into AI in Mississippi!